Contineum (CTNM) announced authorization of its investigational new drug, or IND, application from FDA for PIPE-791 for the treatment of chronic pain associated with two separate indications, ...
The prevalence of radiographic lumbar spondylosis was investigated in a large-scale population study and the association with low back pain was examined. Methods: From a nationwide cohort study ...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...
but it is not clear whether it is a cause or a consequence of knee osteoarthritis. Objective: To determine whether reduced functional performance in the lower extremity predicts the incidence or ...